Wild Ride For Immunology? New Mechanisms, Big Indications Up For US FDA Approval In 2022

Major R&D efforts in immuno-dermatology produced multiple novel candidates in atopic dermatitis and psoriasis, while alopecia areata and vitiligo might see first therapies and JAK safety and COVID-19 logjams resolve.

Wild Metallic Ride
• Source: Alamy

The interrelated fields of immunology and inflammation are positioned for a blockbuster 2022 after a 2021 marred by a US FDA review of safety in the massive Janus kinase inhibitor space and ongoing difficulties in conducting manufacturing inspections during the COVID-19 pandemic.

The year is off to a strong start, with 14 January approvals of two atopic dermatitis (eczema) therapies that hold...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Pink Sheet Perspectives

More from Pink Sheet